Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axsome Thera (AXSM)

Axsome Thera (AXSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,538,952
  • Shares Outstanding, K 50,413
  • Annual Sales, $ 385,690 K
  • Annual Income, $ -287,220 K
  • EBIT $ -206 M
  • EBITDA $ -195 M
  • 60-Month Beta 0.44
  • Price/Sales 15.51
  • Price/Cash Flow N/A
  • Price/Book 115.82

Options Overview Details

View History
  • Implied Volatility 34.86% (-3.17%)
  • Historical Volatility 66.89%
  • IV Percentile 1%
  • IV Rank 3.08%
  • IV High 73.08% on 04/10/25
  • IV Low 33.64% on 01/06/26
  • Expected Move (DTE 3) 4.38 (2.48%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 1,547
  • Volume Avg (30-Day) 1,160
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 26,875
  • Open Int (30-Day) 22,751
  • Expected Range 172.44 to 181.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.75
  • Number of Estimates 10
  • High Estimate -0.52
  • Low Estimate -1.16
  • Prior Year -0.96
  • Growth Rate Est. (year over year) +21.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
145.07 +21.89%
on 12/16/25
184.40 -4.11%
on 12/31/25
+28.65 (+19.34%)
since 12/12/25
3-Month
119.20 +48.34%
on 10/13/25
184.40 -4.11%
on 12/31/25
+55.11 (+45.28%)
since 10/10/25
52-Week
80.98 +118.34%
on 01/13/25
184.40 -4.11%
on 12/31/25
+96.77 (+120.89%)
since 01/10/25

Most Recent Stories

More News
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively  AUVELITY ® preliminary...

AXSM : 176.82 (+4.39%)
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Significant updates from the FDA toward the end of 2025 have rallied investor interest in Axsome and Innoviva, two high-potential biotech names for 2026.

INVA : 19.44 (-0.72%)
AXSM : 176.82 (+4.39%)
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...

AXSM : 176.82 (+4.39%)
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...

AXSM : 176.82 (+4.39%)
Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 176.82 (+4.39%)
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

FBIO : 4.20 (-2.33%)
ATXI : 0.6236 (-16.63%)
AXSM : 176.82 (+4.39%)
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with...

AZN : 93.63 (-1.08%)
ATXI : 0.6236 (-16.63%)
AXSM : 176.82 (+4.39%)
Biologics Market Surges Toward $680B as FDA Accelerates Approval Pathways

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges toward $679.56...

AVAI : 0.5850 (+14.73%)
VRTX : 460.59 (-0.70%)
WST : 272.91 (-0.95%)
RCKT : 3.60 (-3.49%)
AXSM : 176.82 (+4.39%)
Axsome: Q3 Earnings Snapshot

Axsome: Q3 Earnings Snapshot

AXSM : 176.82 (+4.39%)
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY ® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth ...

AXSM : 176.82 (+4.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

See More

Key Turning Points

3rd Resistance Point 190.22
2nd Resistance Point 184.83
1st Resistance Point 180.83
Last Price 176.82
1st Support Level 171.44
2nd Support Level 166.05
3rd Support Level 162.05

See More

52-Week High 184.40
Last Price 176.82
Fibonacci 61.8% 144.89
Fibonacci 50% 132.69
Fibonacci 38.2% 120.49
52-Week Low 80.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar